{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:11:15Z","timestamp":1787242275146,"version":"build-2736575974"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EpiEndo Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glasmacinal (EP395) is an oral macrolide, with immunomodulatory properties like antibiotic macrolides (such as azithromycin), but with negligible in vitro antimicrobial activity, which is being developed as a potential treatment to reduce exacerbations in respiratory conditions. In an open-label healthy participant trial (ClinicalTrials.gov: NCT06118684), with the primary objective of assessing potential drug-drug interactions of glasmacinal, faecal samples were collected to evaluate the impact on the gut microbiota of daily doses of glasmacinal for 2 weeks, using both phenotypic and 16S rRNA gene sequencing. Glasmacinal produced modest effects: reduced phylogenetic richness (p\u2009&lt;\u20090.0001), but not evenness, and altered beta-diversity (PERMANOVA R\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.104 p.adj=0.0018 after 1 week, and\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.059, p.adj=0.028 after 2 weeks) with reductions in\n                    <jats:italic>Clostridiaceae<\/jats:italic>\n                    ,\n                    <jats:italic>Enterobacteriaceae<\/jats:italic>\n                    , and\n                    <jats:italic>Sutterellaceae<\/jats:italic>\n                    abundance. The community shift was approximately 10% after 1-week glasmacinal, and 6% after 2-weeks. With quantitative culture, only Enterobacterales was impacted. No increase or selection of resistance to azithromycin in Enterobacterales and\n                    <jats:italic>Bacteroides<\/jats:italic>\n                    , nor increase in\n                    <jats:italic>Candida spp<\/jats:italic>\n                    . or\n                    <jats:italic>Clostridioides difficile<\/jats:italic>\n                    , were detected. Overall, glasmacinal induced limited restructuring of the gut microbiome (without the defining hallmarks of antibiotic-like dysbiosis), core anaerobic phyla of the gut (Firmicutes and Bacteroidetes) were preserved, and there was no selection of antimicrobial resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-76867-9","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:05:09Z","timestamp":1787220309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of the anti-inflammatory macrolide glasmacinal on the gut microbiota of healthy adults: an open-label trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Tsegaye","family":"Sewunet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-8491","authenticated-orcid":false,"given":"Kate","family":"Hanrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-6122","authenticated-orcid":false,"given":"Christian G.","family":"Giske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"76867_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1124\/pharmrev.121.000300","volume":"73","author":"JA Kricker","year":"2021","unstructured":"Kricker, J. A. et al. Nonantimicrobial actions of macrolides: overview and perspectives for future development. Pharmacol. Rev. 73, 233\u2013262 (2021).","journal-title":"Pharmacol. Rev."},{"key":"76867_CR2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1164\/rccm.201806-1103ED","volume":"198","author":"A Schultz","year":"2018","unstructured":"Schultz, A. & Sly, P. D. Preservation of Lung Function In Cystic Fibrosis: Are Macrolides The Answer? Am. J. Respir. Crit. Care Med. 198, 1114\u20131116 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"76867_CR3","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1111\/bph.13936","volume":"174","author":"GP Dinos","year":"2017","unstructured":"Dinos, G. P. The macrolide antibiotic renaissance. Br. J. Pharmacol. 174, 2967\u20132983 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"76867_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/00325481.2017.1285677","volume":"129","author":"CL Cramer","year":"2017","unstructured":"Cramer, C. L., Patterson, A., Alchakaki, A. & Soubani, A. O. Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgrad. Med. 129, 493\u2013499 (2017).","journal-title":"Postgrad. Med."},{"key":"76867_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","volume":"143","author":"MJ Parnham","year":"2014","unstructured":"Parnham, M. J. et al. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol. Ther. 143, 225\u2013245 (2014).","journal-title":"Pharmacol. Ther."},{"key":"76867_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","volume":"8","author":"TDY Reijnders","year":"2020","unstructured":"Reijnders, T. D. Y., Saris, A., Schultz, M. J. & van der Poll, T. Immunomodulation by macrolides: therapeutic potential for critical care. Lancet Respir. Med. 8, 619\u2013630 (2020).","journal-title":"Lancet Respir. Med."},{"key":"76867_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1753465816682677","volume":"11","author":"S Qiu","year":"2017","unstructured":"Qiu, S. & Zhong, X. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis. 11, 147\u2013155 (2017).","journal-title":"Ther. Adv. Respir. Dis."},{"key":"76867_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert, R. K. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365, 689\u2013698 (2011).","journal-title":"N. Engl. J. Med."},{"key":"76867_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","volume":"2","author":"S Uzun","year":"2014","unstructured":"Uzun, S. et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 2, 361\u2013368 (2014).","journal-title":"Lancet Respir. Med."},{"key":"76867_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","volume":"390","author":"PG Gibson","year":"2017","unstructured":"Gibson, P. G. et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 390, 659\u2013668 (2017).","journal-title":"Lancet"},{"key":"76867_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","volume":"380","author":"C Wong","year":"2012","unstructured":"Wong, C. et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380, 660\u2013667 (2012).","journal-title":"Lancet"},{"key":"76867_CR12","doi-asserted-by":"publisher","first-page":"102095","DOI":"10.1016\/j.pupt.2021.102095","volume":"71","author":"J Pollock","year":"2021","unstructured":"Pollock, J. & Chalmers, J. D. The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm. Pharmacol. Ther. 71, 102095 (2021).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"76867_CR13","doi-asserted-by":"crossref","unstructured":"Southern, K. W., Solis-Moya, A., Kurz, D. & Smith, S. Macrolide antibiotics (including azithromycin) for cystic fibrosis. Cochrane Database Syst. Rev. 2, CD002203 (2024).","DOI":"10.1002\/14651858.CD002203.pub5"},{"key":"76867_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4104\/pcrj.2013.00074","volume":"22","author":"M Miravitlles","year":"2013","unstructured":"Miravitlles, M. Long-term antibiotics in COPD: more benefit than harm? Prim. Care Respir. J. 22, 261\u2013262 (2013).","journal-title":"Prim. Care Respir. J."},{"key":"76867_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40266-020-00786-7","volume":"37","author":"MN Al-Hasan","year":"2020","unstructured":"Al-Hasan, M. N. & Al-Jaghbeer, M. J. Use of antibiotics in chronic obstructive pulmonary disease: what is their current role in older patients? Drugs Aging 37, 627\u2013633 (2020).","journal-title":"Drugs Aging"},{"key":"76867_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12890-017-0541-0","volume":"17","author":"HL Zhang","year":"2017","unstructured":"Zhang, H. L., Tan, M., Qiu, A. M., Tao, Z. & Wang, C. H. Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: A network meta-analysis. BMC Pulm. Med. 17, 196 (2017).","journal-title":"BMC Pulm. Med."},{"key":"76867_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1183\/09031936.00208011","volume":"40","author":"M Yamaya","year":"2012","unstructured":"Yamaya, M. et al. Macrolide effects on the prevention of COPD exacerbations. Eur. Respir. J. 40, 485\u2013494 (2012).","journal-title":"Eur. Respir. J."},{"key":"76867_CR18","doi-asserted-by":"publisher","first-page":"868086","DOI":"10.3389\/fmicb.2022.868086","volume":"13","author":"L Qu","year":"2022","unstructured":"Qu, L., Cheng, Q., Wang, Y., Mu, H. & Zhang, Y. COPD and gut\u2013lung axis: how microbiota and host inflammasome influence COPD and related therapeutics. Front. Microbiol. 13, 868086 (2022).","journal-title":"Front. Microbiol."},{"key":"76867_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12931-024-02802-5","volume":"25","author":"W Xiao","year":"2024","unstructured":"Xiao, W. et al. Bacterial interactome disturbance in chronic obstructive pulmonary disease clinical stability and exacerbations. Respir. Res. 25, 173 (2024).","journal-title":"Respir. Res."},{"key":"76867_CR20","doi-asserted-by":"publisher","first-page":"115150","DOI":"10.1016\/j.biopha.2023.115150","volume":"165","author":"W Song","year":"2023","unstructured":"Song, W., Yue, Y. & Zhang, Q. Imbalance of gut microbiota is involved in the development of chronic obstructive pulmonary disease: a review. Biomed. Pharmacother. 165, 115150 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"76867_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30612","volume":"10","author":"Z Song","year":"2024","unstructured":"Song, Z. et al. The role of gut-lung axis in COPD: pathogenesis, immune response, and prospective treatment. Heliyon 10, e30612 (2024).","journal-title":"Heliyon"},{"key":"76867_CR22","first-page":"311","volume":"11","author":"Z-X Cheng","year":"2024","unstructured":"Cheng, Z.-X. & Zhang, J. Exploring the role of gut-lung interactions in COPD pathogenesis: a comprehensive review on microbiota characteristics and inflammation modulation. Chronic Obstr. Pulm. Dis. 11, 311\u2013325 (2024).","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"76867_CR23","doi-asserted-by":"publisher","first-page":"102363","DOI":"10.1016\/j.pupt.2025.102363","volume":"90","author":"T Gudjonsson","year":"2025","unstructured":"Gudjonsson, T. et al. A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier. Pulm. Pharmacol. Ther. 90, 102363 (2025).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"76867_CR24","doi-asserted-by":"publisher","first-page":"00782","DOI":"10.1183\/23120541.00782-2025","volume":"12","author":"H Watz","year":"2026","unstructured":"Watz, H. et al. A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients. ERJ Open Res. 12, 00782\u201302025 (2026).","journal-title":"ERJ Open Res"},{"key":"76867_CR25","doi-asserted-by":"publisher","first-page":"102364","DOI":"10.1016\/j.pupt.2025.102364","volume":"90","author":"JA Kricker","year":"2025","unstructured":"Kricker, J. A., Norris, V., Page, C. & Parnham, M. J. Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation. Pulm. Pharmacol. Ther. 90, 102364 (2025).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"76867_CR26","doi-asserted-by":"publisher","first-page":"102365","DOI":"10.1016\/j.pupt.2025.102365","volume":"90","author":"JM Hohlfeld","year":"2025","unstructured":"Hohlfeld, J. M. et al. Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial. Pulm. Pharmacol. Ther. 90, 102365 (2025).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"76867_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12038-019-9926-y","volume":"44","author":"B Das","year":"2019","unstructured":"Das, B. & Nair, G. B. Homeostasis and dysbiosis of the gut microbiome in health and disease. J. Biosci. 44, 117 (2019).","journal-title":"J. Biosci."},{"key":"76867_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","volume":"505","author":"LA David","year":"2014","unstructured":"David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559\u2013563 (2014).","journal-title":"Nature"},{"key":"76867_CR29","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3389\/fphar.2020.01153","volume":"11","author":"D Maseda","year":"2020","unstructured":"Maseda, D. & Ricciotti, E. NSAID\u2013gut microbiota interactions. Front. Pharmacol. 11, 1153 (2020).","journal-title":"Front. Pharmacol."},{"key":"76867_CR30","doi-asserted-by":"publisher","first-page":"e0054125","DOI":"10.1128\/msystems.00541-25","volume":"10","author":"O Aasmets","year":"2025","unstructured":"Aasmets, O. et al. A hidden confounder for microbiome studies: medications used years before sample collection. mSystems 10, e0054125 (2025).","journal-title":"mSystems"},{"key":"76867_CR31","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.3390\/ijerph17207618","volume":"17","author":"Z Al Bander","year":"2020","unstructured":"Al Bander, Z., Nitert, M. D., Mousa, A. & Naderpoor, N. The gut microbiota and inflammation: an overview. Int. J. Environ. Res. Public Health 17, 7618 (2020).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"76867_CR32","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1038\/s41564-024-01856-x","volume":"9","author":"N Proch\u00e1zkov\u00e1","year":"2024","unstructured":"Proch\u00e1zkov\u00e1, N. et al. Gut physiology and environment explain variations in human gut microbiome composition and metabolism. Nat. Microbiol. 9, 3210\u20133225 (2024).","journal-title":"Nat. Microbiol."},{"key":"76867_CR33","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/cmi.12308","volume":"16","author":"C Petersen","year":"2014","unstructured":"Petersen, C. & Round, J. L. Defining dysbiosis and its influence on host immunity and disease. Cell. Microbiol. 16, 1024\u20131033 (2014).","journal-title":"Cell. Microbiol."},{"key":"76867_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/gutjnl-2020-321747","volume":"70","author":"M Fassarella","year":"2021","unstructured":"Fassarella, M. et al. Gut microbiome stability and resilience: Elucidating the response to perturbations in order to modulate gut health. Gut. 70, 595\u2013605 (2021).","journal-title":"Gut"},{"key":"76867_CR35","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/phar.2731","volume":"42","author":"MR Bidell","year":"2022","unstructured":"Bidell, M. R., Hobbs, A. L. V. & Lodise, T. P. Gut microbiome health and dysbiosis: a clinical primer. Pharmacotherapy: J. Hum. Pharmacol. Drug Ther. 42, 849\u2013857 (2022).","journal-title":"Pharmacotherapy: J. Hum. Pharmacol. Drug Ther."},{"key":"76867_CR36","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","volume":"113","author":"EZ Gomaa","year":"2020","unstructured":"Gomaa, E. Z. Human gut microbiota\/microbiome in health and diseases: a review. Antonie van. Leeuwenhoek 113, 2019\u20132040 (2020).","journal-title":"Antonie van. Leeuwenhoek"},{"key":"76867_CR37","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/bcp.70509","volume":"92","author":"D Singh","year":"2026","unstructured":"Singh, D. et al. Early clinical pharmacology evaluation of the novel anti-inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions. Br. J. Clin. Pharmacol. 92, 2349\u20132363 (2026).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"76867_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41592-023-02092-7","volume":"21","author":"H Lin","year":"2024","unstructured":"Lin, H. & Peddada, S. Das. Multigroup analysis of compositions of microbiomes with covariate adjustments and repeated measures. Nat. Methods 21, 83\u201391 (2024).","journal-title":"Nat. Methods"},{"key":"76867_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02655-5","volume":"23","author":"H Zhou","year":"2022","unstructured":"Zhou, H., He, K., Chen, J. & Zhang, X. LinDA: linear models for differential abundance analysis of microbiome compositional data. Genome Biol. 23, 95 (2022).","journal-title":"Genome Biol."},{"key":"76867_CR40","doi-asserted-by":"publisher","first-page":"e1003730","DOI":"10.1371\/journal.ppat.1003730","volume":"9","author":"AM Spees","year":"2013","unstructured":"Spees, A. M., Lopez, C. A., Kingsbury, D. D., Winter, S. E. & B\u00e4umler, A. J. Colonization resistance: battle of the bugs or M\u00e9nage \u00e0 Trois with the Host? PLoS Pathog. 9, e1003730 (2013).","journal-title":"PLoS Pathog."},{"key":"76867_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.12563","volume":"279","author":"S Kim","year":"2017","unstructured":"Kim, S., Covington, A. & Pamer, E. G. The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. Immunol. Rev. 279, 90\u2013105 (2017).","journal-title":"Immunol. Rev."},{"key":"76867_CR42","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.clnu.2022.08.029","volume":"41","author":"M-J Liu","year":"2022","unstructured":"Liu, M.-J. et al. Recent findings in Akkermansia muciniphila-regulated metabolism and its role in intestinal diseases. Clin. Nutr. 41, 2333\u20132344 (2022).","journal-title":"Clin. Nutr."},{"key":"76867_CR43","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3389\/fmicb.2016.01706","volume":"7","author":"K Hiippala","year":"2016","unstructured":"Hiippala, K., Kainulainen, V., Kalliom\u00e4ki, M., Arkkila, P. & Satokari, R. Mucosal prevalence and interactions with the epithelium indicate commensalism of Sutterella spp. Front. Microbiol. 7, 1706 (2016).","journal-title":"Front. Microbiol."},{"key":"76867_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrmicro3552","volume":"14","author":"GP Donaldson","year":"2016","unstructured":"Donaldson, G. P., Lee, S. M. & Mazmanian, S. K. Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 14, 20\u201332 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"76867_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51878-3","volume":"9","author":"H Earley","year":"2019","unstructured":"Earley, H. et al. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. Sci. Rep. 9, 15683 (2019).","journal-title":"Sci. Rep."},{"key":"76867_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23980-6","volume":"12","author":"R Filardi","year":"2022","unstructured":"Filardi, R., Gargari, G., Mora, D. & Arioli, S. Characterization of antibiotic-resistance traits in Akkermansia muciniphila strains of human origin. Sci. Rep. 12, 19426 (2022).","journal-title":"Sci. Rep."},{"key":"76867_CR47","doi-asserted-by":"publisher","first-page":"e0083123","DOI":"10.1128\/spectrum.00831-23","volume":"11","author":"JM Choo","year":"2023","unstructured":"Choo, J. M. et al. The impact of long-term macrolide exposure on the gut microbiome and its implications for metabolic control. Microbiol. Spectr. 11, e0083123 (2023).","journal-title":"Microbiol. Spectr."},{"key":"76867_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00408-026-00881-3","volume":"204","author":"JA Kricker","year":"2026","unstructured":"Kricker, J. A., Riffo-Vasquez, Y., Norris, V., Page, C. P. & Parnham, M. J. The effect of the novel macrolide glasmacinal (EP395) on allergen-induced eosinophil infiltration into the lung. Lung 204, 17 (2026).","journal-title":"Lung"},{"key":"76867_CR49","doi-asserted-by":"publisher","first-page":"2614054","DOI":"10.1080\/19490976.2026.2614054","volume":"18","author":"E Tiffany","year":"2026","unstructured":"Tiffany, E., Kim, K. S., Sittipo, P., Lee, D.-W. & Lee, Y. K. Mucin-degrading gut bacteria: context-dependent roles in intestinal homeostasis and disease. Gut Microbes 18, 2614054 (2026).","journal-title":"Gut Microbes"},{"key":"76867_CR50","doi-asserted-by":"publisher","first-page":"110649","DOI":"10.1016\/j.celrep.2022.110649","volume":"39","author":"WE Anthony","year":"2022","unstructured":"Anthony, W. E. et al. Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults. Cell Rep. 39, 110649 (2022).","journal-title":"Cell Rep."},{"key":"76867_CR51","doi-asserted-by":"publisher","first-page":"107250","DOI":"10.1016\/j.micpath.2024.107250","volume":"199","author":"PC Soldavini Pelichotti","year":"2025","unstructured":"Soldavini Pelichotti, P. C. et al. Bifidobacteria antagonize the life cycle of Clostridioides difficile. Microb. Pathog. 199, 107250 (2025).","journal-title":"Microb. Pathog."},{"key":"76867_CR52","doi-asserted-by":"crossref","unstructured":"Collado, M. C., Gueimonde, M., Sanz, Y. & Salminen, S. Adhesion properties and competitive pathogen exclusion ability of bifidobacteria with acquired acid resistance. J. Food Protect. 69, 1675\u22121679 (2006).","DOI":"10.4315\/0362-028X-69.7.1675"},{"key":"76867_CR53","unstructured":"FDA. Highlights of Prescribing Information www.fda.gov\/medwatch (2021)."},{"key":"76867_CR54","doi-asserted-by":"publisher","first-page":"e0224621","DOI":"10.1128\/aac.02246-21","volume":"66","author":"LD Burr","year":"2022","unstructured":"Burr, L. D. et al. Assessment of long-term macrolide exposure on the oropharyngeal microbiome and macrolide resistance in healthy adults and consequences for onward transmission of resistance. Antimicrob. Agents Chemother. 66, e0224621 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"76867_CR55","doi-asserted-by":"crossref","unstructured":"Abotsi, R. E. et al. The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease. ERJ Open Res. 8, 00491\u22122021 (2022).","DOI":"10.1183\/23120541.00491-2021"},{"key":"76867_CR56","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/AAC.02067-13","volume":"58","author":"H Li","year":"2014","unstructured":"Li, H. et al. Meta-Analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob. Agents Chemother. 58, 511\u2013517 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"76867_CR57","doi-asserted-by":"publisher","first-page":"e0158723","DOI":"10.1371\/journal.pone.0158723","volume":"11","author":"S Christianson","year":"2016","unstructured":"Christianson, S. et al. Time-to-detection of inducible macrolide resistance in Mycobacterium abscessus subspecies and its association with the erm(41) sequevar. PLoS ONE 11, e0158723 (2016).","journal-title":"PLoS ONE"},{"key":"76867_CR58","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","volume":"369","author":"S Malhotra-Kumar","year":"2007","unstructured":"Malhotra-Kumar, S., Lammens, C., Coenen, S., Van Herck, K. & Goossens, H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 369, 482\u2013490 (2007).","journal-title":"Lancet"},{"key":"76867_CR59","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria Europe PMC Funders Group. Nature 555, 623\u2013628 (2018).","journal-title":"Nature"},{"key":"76867_CR60","doi-asserted-by":"publisher","first-page":"1559521","DOI":"10.3389\/fmicb.2025.1559521","volume":"16","author":"A Safarchi","year":"2025","unstructured":"Safarchi, A., Al-Qadami, G., Tran, C. D. & Conlon, M. Understanding dysbiosis and resilience in the human gut microbiome: biomarkers, interventions, and challenges. Front. Microbiol. 16, 1559521 (2025).","journal-title":"Front. Microbiol."},{"key":"76867_CR61","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1128\/CMR.00008-07","volume":"20","author":"HM Wexler","year":"2007","unstructured":"Wexler, H. M. Bacteroides: the good, the bad, and the Nitty-Gritty. Clin. Microbiol. Rev. 20, 593\u2013621 (2007).","journal-title":"Clin. Microbiol. Rev."},{"key":"76867_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2020.1848158","volume":"13","author":"H Zafar","year":"2021","unstructured":"Zafar, H. & Saier, M. H. Gut Bacteroides species in health and disease. Gut Microbes 13, 1\u201320 (2021).","journal-title":"Gut Microbes"},{"key":"76867_CR63","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/biology13030142","volume":"13","author":"MI Moreira de Gouveia","year":"2024","unstructured":"Moreira de Gouveia, M. I., Bernalier-Donadille, A. & Jubelin, G. Enterobacteriaceae in the human gut: dynamics and ecological roles in health and disease. Biology 13, 142 (2024).","journal-title":"Biology"},{"key":"76867_CR64","doi-asserted-by":"crossref","unstructured":"Dubin, K. & Pamer, E. G. Enterococci and their interactions with the intestinal microbiome. Microbiol. Spectr. 5, 10\u22121128 (2017).","DOI":"10.1128\/microbiolspec.BAD-0014-2016"},{"key":"76867_CR65","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1093\/cid\/civ137","volume":"60","author":"MU Rashid","year":"2015","unstructured":"Rashid, M. U. et al. Determining the long-term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods. Clin. Infect. Dis. 60, S77\u2013S84 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"76867_CR66","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcimb.2015.00026","volume":"5","author":"Q Yu","year":"2015","unstructured":"Yu, Q., Yuan, L., Deng, J. & Yang, Q. Lactobacillus protects the integrity of intestinal epithelial barrier damaged by pathogenic bacteria. Front. Cell. Infect. Microbiol. 5, 26 (2015).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"76867_CR67","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.3390\/ijms26115226","volume":"26","author":"F Toto","year":"2025","unstructured":"Toto, F., Scanu, M., Gramegna, M., Putignani, L. & Del Chierico, F. Impact of DNA extraction and 16S rRNA gene amplification strategy on microbiota profiling of faecal samples. Int. J. Mol. Sci. 26, 5226 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"76867_CR68","doi-asserted-by":"publisher","first-page":"678522","DOI":"10.3389\/fcimb.2021.678522","volume":"11","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Impact of bead-beating intensity on the genus- and species-level characterization of the gut microbiome using amplicon and complete 16S rRNA gene sequencing. Front. Cell. Infect. Microbiol. 11, 678522 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"76867_CR69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41586-023-06378-w","volume":"620","author":"MT Khan","year":"2023","unstructured":"Khan, M. T. et al. Synergy and oxygen adaptation for development of next-generation probiotics. Nature 620, 381\u2013385 (2023).","journal-title":"Nature"},{"key":"76867_CR70","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/microorganisms13071647","volume":"13","author":"M Terlizzi","year":"2025","unstructured":"Terlizzi, M., Speranza, B., Sinigaglia, M., Corbo, M. R. & Bevilacqua, A. Antibiotic resistance in bifidobacterium animalis subsp. lactis and bifidobacterium longum: definition of sensitivity\/resistance profiles at the species level. Microorganisms 13, 1647 (2025).","journal-title":"Microorganisms"},{"key":"76867_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/jac\/dkh495","volume":"55","author":"C Moubareck","year":"2005","unstructured":"Moubareck, C., Gavini, F., Vaugien, L., Butel, M. J. & Doucet-Populaire, F. Antimicrobial susceptibility of bifidobacteria. J. Antimicrob. Chemother. 55, 38\u201344 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"76867_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42423-3","volume":"9","author":"C Gomes","year":"2019","unstructured":"Gomes, C., Ruiz-Rold\u00e1n, L., Mateu, J., Ochoa, T. J. & Ruiz, J. Azithromycin resistance levels and mechanisms in Escherichia coli. Sci. Rep. 9, 6089 (2019).","journal-title":"Sci. Rep."},{"key":"76867_CR73","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jac\/41.3.387","volume":"41","author":"LM Edine","year":"1998","unstructured":"Edine, L .M., Jacobs, M. R. & Appelbaum, P. C. Anti-anaerobic activity of erythromycin, azithromycin and clarithromycin: effect of pH adjustment of media to compensate for pH shift caused by incubation in CO2. J. Antimicrob. Chemother. 41, 387\u2013389 (1998).","journal-title":"J. Antimicrob. Chemother."},{"key":"76867_CR74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s43705-023-00266-0","volume":"3","author":"Y Gao","year":"2023","unstructured":"Gao, Y. & Wu, M. Accounting for 16S rRNA copy number prediction uncertainty and its implications in bacterial diversity analyses. ISME Commun. 3, 59 (2023).","journal-title":"ISME Commun."},{"key":"76867_CR75","doi-asserted-by":"publisher","unstructured":"Mohammad, R. Karolinska-AMR\/q2-pipeline: q2-pipeline v1.0.0 Glasmacinal gut microbiome study(Version v1.0.0) [Computer software]. https:\/\/doi.org\/10.5281\/zenodo.21453180 (2026).","DOI":"10.5281\/zenodo.21453180"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76867-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76867-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76867-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:03:27Z","timestamp":1787227407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76867-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76867"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76867-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Three authors T.S., M.R., and C.G.G. have none to declare. VN, KH and JK are employees of EpiEndo Pharmaceuticals and are included in the company\u2019s Employee Stock Option Plan.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8728"}}